Latif RACHDI

Dr. Latif RACHDI

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2012 in Diabetes
Verified
Journal Article
Open access
LRLatif RACHDI
Latif RACHDI
VAVirginie Aïello
Virginie Aïello
BDBertrand Duvillié
Bertrand Duvillié
RSRaphaël Scharfmann
Raphaël Scharfmann
Leucine (Leu) is an essential branched-chain amino acid, which activates the mammalian target of rapamycin (mTOR) signaling pathway. The effect of Leu on cell differentiation during embryonic development is unknown. Here, we show that Leu supplementation during pregnancy significantly increased fetal body weight, caused fetal hyperglycemia and hypoinsulinemia, and decreased the relative islet area. We also used rat embryonic pancreatic explant culture for elucidating the mechanism of Leu action on β-cell development. We found that in the presence of Leu, differentiation of pancreatic duodenal homeobox-1–positive progenitor cells into neurogenin3-positive endocrine progenitor cells was inefficient and resulted in decreased β-cell formation. Mechanistically, Leu increases the intracellular levels of hypoxia-inducible factor 1-α, a repressor of endocrine fate in the pancreas, by activating the mTOR complex 1 signaling pathway. Collectively, our findings indicate that Leu supplementation during pregnancy could potentially increase the risk of type 2 diabetes mellitus by inhibiting the differentiation of pancreatic endocrine progenitor cells during a susceptible period of fetal life.

28 May 2014 in Cell Cycle
Verified
Journal Article
Closed access
LRLatif RACHDI
Latif RACHDI
DKDulanjalee Kariyawasam
Dulanjalee Kariyawasam
VAVirginie Aïello
Virginie Aïello
YHYann Herault
Yann Herault
NJNathalie Janel
Nathalie Janel
RSRaphaël Scharfmann
Raphaël Scharfmann
Type 2 diabetes is caused by a limited capacity of insulin-producing pancreatic β cells to increase their mass and function in response to insulin resistance. The signaling pathways that positively...

16 February 2021 in Gut
Verified
Journal Article
Closed access
PDF file
MRMatthieu Rouland
Matthieu Rouland
LBLucie Beaudoin
Lucie Beaudoin
OROphélie Rouxel
Ophélie Rouxel
LBLéo Bertrand
Léo Bertrand
LCLucie Cagninacci
Lucie Cagninacci
ALAgnès Lehuen
Agnès Lehuen
Objective Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of pancreatic β-cells producing insulin. Both T1D patients and animal models exhibit gut microbiota and mucosa alterations, although the exact cause for these remains poorly understood. We investigated the production of key cytokines controlling gut integrity, the abundance of segmented filamentous bacteria (SFB) involved in the production of these cytokines, and the respective role of autoimmune inflammation and hyperglycaemia. Design We used several mouse models of autoimmune T1D as well as mice rendered hyperglycaemic without inflammation to study gut mucosa and microbiota dysbiosis. We analysed cytokine expression in immune cells, epithelial cell function, SFB abundance and microbiota composition by 16S sequencing. We assessed the role of anti-tumour necrosis factor α on gut mucosa inflammation and T1D onset. Results We show in models of autoimmune T1D a conserved loss of interleukin (IL)-17A, IL-22 and IL-23A in gut mucosa. Intestinal epithelial cell function was altered and gut integrity was impaired. These defects were associated with dysbiosis including progressive loss of SFB. Transfer of diabetogenic T-cells recapitulated these gut alterations, whereas induction of hyperglycaemia with no inflammation failed to do so. Moreover, anti-inflammatory treatment restored gut mucosa and immune cell function and dampened diabetes incidence. Conclusion Our results demonstrate that gut mucosa alterations and dysbiosis in T1D are primarily linked to inflammation rather than hyperglycaemia. Anti-inflammatory treatment preserves gut homeostasis and protective commensal flora reducing T1D incidence.

10 August 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LRLatif RACHDI
Latif RACHDI
AMAlicia Maugein
Alicia Maugein
SPSeverine Pechberty
Severine Pechberty
MAMathieu Armanet
Mathieu Armanet
JHJuliette Hamroune
Juliette Hamroune
RSRaphael Scharfmann
Raphael Scharfmann
G protein-coupled receptors are seven transmembrane signaling molecules that are involved in a wide variety of physiological processes. They constitute a large protein family of receptors with almost 300 members detected in human pancreatic islet preparations. However, the functional role of these receptors in pancreatic islets is unknown in most cases. We generated a new stable human beta cell line from neonatal pancreas. This cell line, named ECN90 expresses both subunits (GABBR1 and GABBR2) of the metabotropic GABAB receptor compared to human islet. In ECN90 cells, baclofen, a specific GABAB receptor agonist, inhibits cAMP signaling causing decreased expression of beta cell-specific genes such as MAFA and PCSK1, and reduced insulin secretion. We next demonstrated that in primary human islets, GABBR2 mRNA expression is strongly induced under cAMP signaling, while GABBR1 mRNA is constitutively expressed. We also found that induction and activation of the GABAB receptor in human islets modulates insulin secretion.

30 January 2014 in Diabetologia
Verified
Journal Article
Closed access
PDF file
LRLatif RACHDI
Latif RACHDI
DKDulanjalee Kariyawasam
Dulanjalee Kariyawasam
FGFanny Guez
Fanny Guez
VAVirginie Aïello
Virginie Aïello
MAMaria L. Arbonés
Maria L. Arbonés
RSRaphaël Scharfmann
Raphaël Scharfmann

25 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
CCCéline Cruciani-Guglielmacci
Céline Cruciani-Guglielmacci
KMKelly Meneyrol
Kelly Meneyrol
JDJessica Denom
Jessica Denom
NKNadim Kassis
Nadim Kassis
LRLatif RACHDI
Latif RACHDI
NJNathalie Janel
Nathalie Janel
Cystathionine beta synthase (CBS) catalyzes the first step of the transsulfuration pathway from homocysteine to cystathionine, and its deficiency leads to hyperhomocysteinemia (HHcy) in humans and rodents. To date, scarce information is available about the HHcy effect on insulin secretion, and the link between CBS activity and the setting of type 2 diabetes is still unknown. We aimed to decipher the consequences of an inborn defect in CBS on glucose homeostasis in mice. We used a mouse model heterozygous for CBS (CBS+/−) that presented a mild HHcy. Other groups were supplemented with methionine in drinking water to increase the mild to intermediate HHcy, and were submitted to a high-fat diet (HFD). We measured the food intake, body weight gain, body composition, glucose homeostasis, plasma homocysteine level, and CBS activity. We evidenced a defect in the stimulated insulin secretion in CBS+/− mice with mild and intermediate HHcy, while mice with intermediate HHcy under HFD presented an improvement in insulin sensitivity that compensated for the decreased insulin secretion and permitted them to maintain a glucose tolerance similar to the CBS+/+ mice. Islets isolated from CBS+/− mice maintained their ability to respond to the elevated glucose levels, and we showed that a lower parasympathetic tone could, at least in part, be responsible for the insulin secretion defect. Our results emphasize the important role of Hcy metabolic enzymes in insulin secretion and overall glucose homeostasis.